Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(R)-pyridin-4-yl[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanol is a small molecule belonging to the class of phenol ethers, which are aromatic compounds containing an ether group substituted with a benzene ring. It has been studied as a fragment in structure-based drug discovery, particularly in the context of leukotriene A₄ hydrolase (LTA₄H) inhibition. The compound was identified as part of a fragment library used to interrogate protein active sites and allosteric binding sites for fragment binding, and it was found to bind LTA₄H by X-ray crystallography. However, there is no evidence of clinical development or approval for any indication[5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (r)-pyridin-4-yl[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanol.